非小细胞肺癌中Cbl家族表达与临床病理及预后的关系

doi:10.3760/cma.j.issn.1007-1245.2024.13.012

摘要/Abstract

摘要：

目的　检测非小细胞肺癌（NSCLC）中E3泛素连接酶Cbl家族c-Cbl、Cbl-b、Cbl-c蛋白表达水平，并分析其与临床病理、预后的关系。方法　本研究为前瞻性研究。选取2020年1月至2023年1月在汉中市人民医院治疗的NSCLC患者102例作为研究对象，其中男78例、女24例，年龄（67.49±8.33）岁。选取手术切除的癌旁组织作为对照。免疫组织化学染色法检测癌组织、癌旁组织c-Cbl、Cbl-b、Cbl-c蛋白表达。收集患者临床病理特征（性别、年龄、吸烟史、病灶位置、TNM分期、组织分化程度、病理类型、胸膜侵袭），并对比患者癌组织c-Cbl、Cbl-b、Cbl-c蛋白表达；用Cox回归模型分析NSCLC预后的影响因素。绘制Kaplan-Meier曲线分析癌组织Cbl-b、Cbl-c蛋白表达与NSCLC预后的关系。统计学方法采用t检验、χ²检验。结果　癌组织c-Cbl、Cbl-b、Cbl-c蛋白表达阳性率均高于癌旁组织［52.94%（54/102）比37.25%（38/102）、63.73%（65/102）比43.14%（44/102）、67.65%（69/102）比39.22%（40/102）］，差异均有统计学意义（χ²=5.068、8.688、16.568，均P<0.05）。有吸烟史、TNM分期Ⅲ期、未/低分化、胸膜侵袭患者癌组织c-Cbl、Cbl-b、Cbl-c蛋白表达均高于无吸烟史、TNM分期Ⅰ/Ⅱ期、中/高分化、无胸膜侵袭患者［吸烟史：62.32%（43/69）比33.33%（11/33）、73.91%（51/69）比42.42%（14/33）、78.26%（54/69）比45.45%（15/33）；TNM分期：76.00%（19/25）比45.45%（35/77）、88.00%（22/25）比55.84%（43/77）、92.00%（23/25）比59.74%（46/77）；组织分化程度：65.22%（30/46）比42.86%（24/56）、78.26%（36/46）比51.79%（29/56）、82.61%（38/46）比55.36%（31/56）；胸膜侵袭：80.00%（20/25）比44.16%（34/77）、88.00%（22/25）比55.84%（43/77）、92.00%（23/25）比59.74%（46/77）］，差异均有统计学意义（χ²=7.528、9.575、10.978、7.068、8.442、8.974、5.068、7.658、8.570、9.733、8.442、8.974，均P<0.05）。Cox回归分析显示，吸烟史、TNM分期Ⅲ期、未/低分化、胸膜侵袭、癌组织Cbl-b蛋白表达、癌组织Cbl-c蛋白表达是NSCLC患者预后的影响因素（均P<0.05）。Cbl-b阳性组无进展生存时间为27个月（95%CI 22.602～31.398），Cbl-b阴性组无进展生存时间为40个月（95%CI 28.810～51.190），Kaplan-Meier生存曲线总体比较，差异有统计学意义（χ²=6.709，P=0.010）；Cbl-c阳性组无进展生存时间为28个月（95%CI 23.786～32.214），Cbl-c阴性组无进展生存时间为39个月（95%CI 29.892～48.108），Kaplan-Meier生存曲线总体比较，差异有统计学意义（χ²=4.605，P=0.032）。结论　NSCLC中c-Cbl、Cbl-b、Cbl-c蛋白高表达，三者均与吸烟史、TNM分期、分化程度及胸膜侵袭相关，其中Cbl-b、Cbl-c是NSCLC预后的影响因素。

关键词:

非小细胞肺癌, E3泛素连接酶Cbl家族, 临床病理, 预后

Abstract:

Objective　To detect the expression levels of Cbl-b, c-Cbl, and Cbl-c proteins of E3 ubiquitin ligase casitas b-lineage lymphoma (Cbl) family in non-small cell lung cancer (NSCLC), and to analyze their relationship with clinicopathological features and prognosis. Methods　This was a prospective study. A total of 102 patients with NSCLC admitted to Hanzhong People's Hospital from January 2020 to January 2023 were selected, including 78 males and 24 females. They were (67.49±8.33) years old. The cancer-adjacent tissues removed by surgery were used as controls. The immunohistochemical staining was used to detect the expressions of Cbl-b, c-Cbl, and Cbl-c proteins in the cancer tissues and cancer-adjacent tissues. The expressions of Cbl-b, c-Cbl, and Cbl-c proteins in the cancer tissues of the patients with different clinicopathological characteristics (gender, age, smoking history, lesion site, TNM stage, differentiation grade, pathological type, and pleural invasion) were compared. The Cox regression model was used to analyze the influencing factors of the patients' prognosis. Kaplan-Meier curves were drawn to analyze the relationship between the expressions of Cbl-b and Cbl-c proteins in the cancer tissues and NSCLC prognosis. t and χ² tests were applied. Results　The positive expression rates of Cbl-b, c-Cbl, and Cbl-c proteins in the cancer tissues were higher than those in the cancer-adjacent tissues [52.94% (54/102) vs. 37.25% (38/102), 63.73% (65/102) vs. 43.14% (44/102), and 67.65% (69/102) vs. 39.22% (40/102)], with statistical differences (χ²=5.068, 8.688, and 16.568; all P<0.05). The positive expression rates of Cbl-b, c-Cbl, and Cbl-c proteins in the cancer tissues of the patients with smoking history, TNM stage Ⅲ/Ⅳ, undifferentiated/low differentiation, and pleural invasion were higher than those of the patients without smoking history and with TNM stage I/Ⅱ, moderate/high differentiation, and no pleural invasion [smoking history: 62.32% (43/69) vs. 33.33% (11/33), 73.91% (51/69) vs. 42.42% (14/33),and 78.26% (54/69) vs. 45.45% (15/33); TNM stage: 76.00% (19/25) vs. 45.45% (35/77), 88.00% (22/25) vs. 55.84% (43/77), and 92.00% (23/25) vs. 59.74% (46/77); differentiation: 65.22% (30/46) vs. 42.86% (24/56), 78.26% (36/46) vs. 51.79% (29/56), and 82.61% (38/46) vs. 55.36% (31/56); pleural invasion: 80.00% (20/25) vs. 44.16% (34/77), 88.00% (22/25) vs. 55.84% (43/77), and 92.00% (23/25) vs. 59.74% (46/77)], with statistical differences (χ²=7.528, 9.575, 10.978, 7.068, 8.442, 8.974, 5.068, 7.658, 8.570, 9.733, 8.442, and 8.974; all P<0.05). The Cox regression analysis showed that smoking history, TNM stage Ⅲ, undifferentiated/low differentiation, pleural invasion, and Cbl-b protein expression and Cbl-c protein expression in the cancer tissues were the influencing factors of the patients' prognosis (all P<0.05). The progression-free survival time of the Cbl-b positive group was 27 months (95%CI 22.602-31.398 months), and that of Cbl-b negative group was 40 months (95%CI 28.810-51.190 months); the overall comparison of Kaplan-Meier survival curves showed a statistical difference (χ²=6.709, P=0.010). The progression-free survival time of the Cbl-c positive group was 28 months (95%CI 23.786-32.214 months), and that of the Cbl-c negative group was 39 months (95%CI 29.892-48.108 months); the overall comparison of Kaplan-Meier survival curves showed a statistical difference (χ²=4.605, P=0.032). Conclusions　Cbl-b, c-Cbl, and Cbl-c proteins are highly expressed in NSCLC. All the three are related to smoking history, TNM stage, differentiation degree, and pleural invasion. Among them, Cbl-b and Cbl-c are influencing factors of prognosis of patients with NSCLC.

Key words:

Non-small cell lung cancer, E3 ubiquitin ligase Cbl family, Clinicopathology, Prognosis

孙静黄佳琛.

非小细胞肺癌中Cbl家族表达与临床病理及预后的关系 [J]. 国际医药卫生导报, 2024, 30(13): 2174-2180.

Sun Jing, Huang Jiachen.

Expression of Cbl family in non-small cell lung cancer and its relationship with clinicopathology and prognosis [J]. International Medicine and Health Guidance News, 2024, 30(13): 2174-2180.

参考文献

[1] Oliver AL. Lung cancer: epidemiology and screening[J].Surg Clin North Am,2022,102(3):335-344.DOI:10.1016/j.suc.2021.12.001.
[2] Lee E, Kazerooni EA. Lung cancer screening[J]. Semin Respir Crit Care Med,2022,43(6):839-850.DOI:10.1055/s-0042-1757885.
[3] Ettinger DS, Wood DE, Aisner DL,et al. Non-small cell lung cancer, version 3.2022, NCCN clinical practice guidelines in oncology[J]. J Natl Compr Canc Netw,2022,20(5):497-530.DOI:10.6004/jnccn.2022.0025.
[4] Chen P, Liu Y, Wen Y, et al. Non-small cell lung cancer in China[J].Cancer Commun (Lond),2022,42(10):937-970.DOI:10.1002/cac2.12359.
[5] Leardini D, Messelodi D, Muratore E, et al. Role of CBL mutations in cancer and Non-Malignant Phenotype[J].Cancers (Basel),2022,14(3):839.DOI:10.3390/cancers14030839.
[6] Chen H, Bai Y, Kobayashi M, et al. PRL2 phosphatase enhances oncogenic FLT3 signaling via dephosphorylation of the E3 ubiquitin ligase CBL at tyrosine 371[J].Blood,2023,141(3):244-259.DOI:10.1182/blood.2022016580.
[7] 中国抗癌协会肺癌专业委员会. 2010中国肺癌临床指南:中国肺癌临床指南[M].北京:人民卫生出版社,2010:15-16.
[8] Suazo-Zepeda E, Bokern M, Vinke PC, et al. Risk factors for adverse events induced by immune checkpoint inhibitors in patients with non-small-cell lung cancer: a systematic review and meta-analysis[J].Cancer Immunol Immunother,2021,70(11):3069-3080.DOI:10.1007/s00262-021-02996-3.
[9] Aredo JV, Luo SJ, Gardner RM, et al. Tobacco smoking and risk of second primary lung cancer[J].J Thorac Oncol,2021,16(6):968-979.DOI:10.1016/j.jtho.2021.02.024.
[10] Khan FH, Bhat BA, Sheikh BA, et al. Microbiome dysbiosis and epigenetic modulations in lung cancer: from pathogenesis to therapy[J].Semin Cancer Biol,2022,86(Pt 3):732-742.DOI:10.1016/j.semcancer.2021.07.005.
[11] Roy-Chowdhuri S. Molecular pathology of lung cancer[J].Surg Pathol Clin,2021,14(3):369-377.DOI:10.1016/j.path.2021.05.002.
[12] Wang J, Gong M, Fan X, et al. Autophagy-related signaling pathways in non-small cell lung cancer[J].Mol Cell Biochem,2022,477(2):385-393.DOI:10.1007/s11010-021-04280-5.
[13] Wang H, Wu S, Li Z, et al. Molecular subtyping of small-cell lung cancer based on mutational signatures with different genomic features and therapeutic strategies[J].Cancer Sci,2023,114(2):665-679.DOI:10.1111/cas.15606.
[14] 彭艳艳,李聪,张欣宇. 非小细胞肺癌组织中miR-92a、miR-196b表达水平及其临床意义[J]. 实用癌症杂志,2021,36(9):1421-1425.DOI:10.3969/j.issn.1001-5930. 2021.09.008.
[15] 王楠,姜京京,梁珊珊,等. 非小细胞肺癌患者微创切除术后复发与转移的相关因素分析[J]. 实用癌症杂志,2022,37(10):1635-1638.DOI:10.3969/j.issn.1001-5930. 2022.10.018.
[16] Sabnis RW. Novel lactams as CBL-B inhibitors for treating cancer[J].ACS Med Chem Lett,2023,14(7):897-898.DOI:10.1021/acsmedchemlett.3c00247.
[17] Tarvestad-Laise K, Ceresa BP. Knockout of c-Cbl/Cbl-b slows c-Met trafficking resulting in enhanced signaling in corneal epithelial cells[J].J Biol Chem,2023,299(10):105233.DOI:10.1016/j.jbc.2023.105233.
[18] Wang S, Xu L, Che X, et al. E3 ubiquitin ligases Cbl-b and c-Cbl downregulate PD-L1 in EGFR wild-type non-small cell lung cancer[J].FEBS Lett,2018,592(4):621-630.DOI:10.1002/1873-3468.12985.
[19] Zhang S, Jia X, Dai H, et al. SERPINE2 promotes liver cancer metastasis by inhibiting c-Cbl-mediated EGFR ubiquitination and degradation[J].Cancer Commun (Lond),2024,44(3):384-407.DOI:10.1002/cac2.12527.
[20] Pinilla-Macua I, Sorkin A. Cbl and Cbl-b independently regulate EGFR through distinct receptor interaction modes[J].Mol Biol Cell,2023,34(13):ar134.DOI:10.1091/mbc.E23-02-0058.
[21] Song L, Zhang L, Zhou Y, et al. ORP5 promotes tumor metastasis via stabilizing c-Met in renal cell carcinoma[J].Cell Death Discov,2022,8(1):219.DOI:10.1038/s41420-022-01023-3.
[22] Lyle C, Richards S, Yasuda K, et al. c-Cbl targets PD-1 in immune cells for proteasomal degradation and modulates colorectal tumor growth[J].Sci Rep,2019,9(1):20257.DOI:10.1038/s41598-019-56208-1.
[23] 张邢松,沈蓉,朱兴华,等. E3泛素连接酶Cbl家族在子宫颈鳞状细胞癌中的表达及临床意义[J]. 南京医科大学学报(自然科学版),2023,43(1):34-39.DOI:10.7655/NYDXBNS20230105.
[24] Chang R, Qi S, Wu Y, et al. Nomograms integrating CT radiomic and deep learning signatures to predict overall survival and progression-free survival in NSCLC patients treated with chemotherapy[J].Cancer Imaging,2023,23(1):101.DOI:10.1186/s40644-023-00620-4.
[25] Ream S, Natarajan P, Gupta S, et al. Paraneoplastic hypereosinophilia in poorly differentiated adenocarcinoma of the lung[J].Cureus,2023,15(1):e34386.DOI:10.7759/cureus.34386.
[26] Ren J, Ren J, Wang K, et al. The location of visceral pleural invasion in stage IB patients with non-small cell lung cancer: comparison and prognosis[J].Eur J Surg Oncol,2023,49(5):950-957.DOI:10.1016/j.ejso.2023.01.022.
[27] Zeng Q, Tang N, Ma Y, et al. Cbl-b restrains priming of pathogenic Th17 cells via the inhibition of IL-6 production by macrophages[J].iScience,2022,25(10):105151.DOI:10.1016/j.isci.2022.105151.
[28] Daniels SR, Liyasova M, Kales SC, et al. Loss of function Cbl-c mutations in solid tumors[J].PLoS One,2019,14(7):e0219143.DOI:10.1371/journal.pone.0219143.
[29] Han S, Liu ZQ, Chung DC, et al. Overproduction of IFNγ by Cbl-b-deficient CD8+ T cells provides resistance against regulatory T cells and induces potent antitumor immunity[J].Cancer Immunol Res,2022,10(4):437-452.DOI:10.1158/2326-6066.CIR-20-0973.
[30] Kimani SW, Perveen S, Szewezyk M, et al. The co-crystal structure of Cbl-b and a small-molecule inhibitor reveals the mechanism of Cbl-b inhibition[J].Commun Biol,2023,6(1):1272.DOI:10.1038/s42003-023-05655-8.
[31] Li H, Zhang J, Ke JR, et al. Pro-prion, as a membrane adaptor protein for E3 ligase c-Cbl, facilitates the ubiquitination of IGF-1R, promoting melanoma metastasis[J].Cell Rep,2022,41(12):111834.DOI:10.1016/j.celrep.2022.111834.